Sign In
Buy BNGO
$1.30
+0.0400 (+3.17%)
At Close: Jun 03, 2026
Bionano Genomics, Inc. (BNGO) Q3 2024 Earnings Call Transcript
07:11pm, Wednesday, 13'th Nov 2024
Bionano Genomics, Inc. (NASDAQ:BNGO ) Q3 2024 Earnings Call Transcript November 13, 2024 4:30 PM ET Company Participants David Holmes - IR Erik Holmlin - CEO and Principal Financial Officer Conference
Bionano Reports Third Quarter 2024 Results and Highlights Recent Business Progress
04:01pm, Wednesday, 13'th Nov 2024
Q3 2024 revenue was $6.1 million, which comprises $6.6 million in core product and software sales which is offset by $0.5 million because of a write-down of aged receivables tied to discontinued clini
Dublin, Nov. 04, 2024 (GLOBE NEWSWIRE) -- The "Optical Genome Mapping Market Size, Share & Trends Analysis, 2024-2030" report has been added to ResearchAndMarkets.com's offering. The global optical ge
Bionano Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
04:30pm, Thursday, 31'st Oct 2024
SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the closing of its previously announced registered direct offering priced at-the-marker under Nasdaq
Bionano Adjourns Special Meeting of Stockholders to November 27, 2024
08:10am, Thursday, 31'st Oct 2024
SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that it adjourned its reconvened Special Meeting of Stockholders originally held on October 2, 2024 a
Bionano Announces Preliminary 3Q 2024 Revenues and Cash
08:00am, Thursday, 10'th Oct 2024
SAN DIEGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced select preliminary results for the quarter ended September 30, 2024. The Company now expects revenue
Bears are Losing Control Over Bionano Genomics (BNGO), Here's Why It's a 'Buy' Now
10:55am, Friday, 06'th Sep 2024
Bionano Genomics (BNGO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement amo
Bionano Genomics, Inc. (BNGO) Canaccord Genuity 44th Annual Growth Conference (Transcript)
07:23pm, Tuesday, 13'th Aug 2024
Bionano Genomics, Inc. (NASDAQ:BNGO ) Canaccord Genuity 44th Annual Growth Results Conference August 13, 2024 3:30 PM ET Company Participants Erik Holmlin - President and Chief Executive Officer Confe
Bionano Genomics (BNGO) Upgraded to Buy: Here's Why
01:00pm, Tuesday, 13'th Aug 2024
Bionano Genomics (BNGO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Bionano Reports Second Quarter 2024 Results and Highlights Recent Business Progress
04:01pm, Wednesday, 07'th Aug 2024
Q2 2024 revenue was $7.8 million, which represents a 10% decrease from Q2 2023 Total installed base of 363 optical genome mapping (OGM) systems as of Q2 2024, which represents a 29% increase over Q2 2
Bionano to Present at the Canaccord Genuity 44th Annual Growth Conference
04:01pm, Wednesday, 31'st Jul 2024
SAN DIEGO, July 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano's president and chief executive officer, will present at the Canaccor
Bionano Announces Closing of up to $30 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
05:25pm, Monday, 08'th Jul 2024
$10 million upfront with up to an additional $20 million upon the exercise in full of clinical milestone-linked Series Warrants $10 million upfront with up to an additional $20 million upon the exerci
Bionano Announces up to $30 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
08:00am, Friday, 05'th Jul 2024
$10 million upfront with up to an additional $20 million upon the exercise in full of clinical milestone-linked Series Warrants $10 million upfront with up to an additional $20 million upon the exerci
SAN DIEGO, July 02, 2024 (GLOBE NEWSWIRE) -- Bionano Laboratories, a clinical laboratory services business of Bionano Genomics, Inc. (Nasdaq: BNGO), today announced that optical genome mapping (OGM) w
Bionano Announces Software Marketing Agreement with Revvity for Newborn Sequencing Research
08:00am, Thursday, 20'th Jun 2024
Bionano has entered into a software marketing agreement with Revvity, Inc. (Revvity) under which Revvity will market and commercialize Bionano's VIA™ software to Revvity's next generation sequencing
